• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受精神分裂症患者使用药用大麻替代大麻。

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia.

机构信息

Department of Psychiatry, Academic Medical Center, University of Amsterdam, P.O. Box 22660, 1100 DD, Amsterdam, The Netherlands.

Jellinek-Arkin, P.O. Box 75848, 1070 AV, Amsterdam, The Netherlands.

出版信息

Harm Reduct J. 2018 Sep 20;15(1):47. doi: 10.1186/s12954-018-0253-7.

DOI:10.1186/s12954-018-0253-7
PMID:30236118
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6149068/
Abstract

BACKGROUND

Cannabis-smoking patients with a psychotic disorder have poorer disease outcomes than non-cannabis-smoking patients with poorest outcomes in patients smoking high-potency cannabis (HPC) containing high Δ9-tetrahydrocannabinol (THC) and low cannabidiol (CBD). Quitting cannabis smoking or substitution of HPC by cannabis variants containing less THC and/or more CBD may benefit these patients. The present study explores whether daily HPC-smoking patients with schizophrenia accept smoking such variants.

METHODS

Twelve male patients were asked to smoke on six different occasions one joint: on two occasions, the cannabis they routinely smoke (HPC; not blind), and blind in random order; on two occasions, cannabis containing low THC and no CBD; and on two occasions, cannabis containing low THC and high CBD.

RESULTS

Both substitute variants were appreciated, but patients preferred the HPC they usually smoked. The effect of the low THC/high CBD variant was reported by 32% to be too short and by 36% to be not strong enough, whereas this was reported by 5% and 64%, respectively, for the low THC cannabis variant.

CONCLUSIONS

Based on these findings, a larger and longer study on the efficacy of cannabis substitution treatment in HPC-smoking patients with schizophrenia seems feasible and should be considered.

TRIAL REGISTRATION

2014-005540-17NL . Registered 22 October 2014, 2014-005540-17NL 20141215 CTA.xml.

摘要

背景

与不吸烟的精神病患者相比,吸食高浓度大麻(HPC)的精神病患者(HPC 中含有高浓度四氢大麻酚(THC)和低浓度大麻二酚(CBD))的预后更差。戒烟或用 THC 含量低和/或 CBD 含量高的大麻变体替代 HPC 可能对这些患者有益。本研究探讨了患有精神分裂症的每日 HPC 吸烟患者是否接受吸食此类变体。

方法

要求 12 名男性患者在六个不同场合吸食一支大麻:两种情况是吸食他们通常吸食的大麻(HPC;非盲),并随机盲吸;两种情况是吸食 THC 含量低且不含 CBD 的大麻;还有两种情况是吸食 THC 含量低但 CBD 含量高的大麻。

结果

两种替代变体都受到了赞赏,但患者更喜欢他们通常吸食的 HPC。32%的患者报告低 THC/高 CBD 变体的效果太短,36%的患者报告效果不够强,而低 THC 大麻变体的报告比例分别为 5%和 64%。

结论

基于这些发现,对 HPC 吸烟的精神分裂症患者进行大麻替代治疗的疗效进行更大规模和更长时间的研究似乎是可行的,应该考虑进行。

试验注册

2014-005540-17NL。2014 年 10 月 22 日注册,2014-005540-17NL 20141215 CTA.xml。

相似文献

1
Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia.接受精神分裂症患者使用药用大麻替代大麻。
Harm Reduct J. 2018 Sep 20;15(1):47. doi: 10.1186/s12954-018-0253-7.
2
Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.血清中 Δ9-四氢大麻酚和大麻二酚的时间进程:区分轻度吸食大麻与非法和医用大麻的使用。
Ther Drug Monit. 2020 Feb;42(1):151-156. doi: 10.1097/FTD.0000000000000683.
3
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.口服大麻二酚不会改变吸食大麻的主观、强化或心血管效应。
Neuropsychopharmacology. 2016 Jul;41(8):1974-82. doi: 10.1038/npp.2015.367. Epub 2015 Dec 28.
4
A preliminary investigation of lung availability of cannabinoids by smoking marijuana or dabbing BHO and decarboxylation rate of THC- and CBD-acids.通过吸食大麻或涂抹大麻提取物对大麻素的肺部可用性以及四氢大麻酚酸和大麻二酚酸的脱羧率进行的初步调查。
Forensic Sci Int. 2019 Feb;295:207-212. doi: 10.1016/j.forsciint.2018.12.021. Epub 2019 Jan 6.
5
Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.Δ9-四氢大麻酚和大麻二酚的治疗用途:一种制备大麻基橄榄油的新提取方法的评估
Curr Pharm Biotechnol. 2017;18(10):828-833. doi: 10.2174/1389201019666171129175655.
6
Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.基于大麻的药物——GW制药公司:高CBD、高THC、药用大麻——GW制药公司,THC与CBD比例
Drugs R D. 2003;4(5):306-9. doi: 10.2165/00126839-200304050-00005.
7
Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.横断面和前瞻性研究大麻效力、剂量和吸烟行为与大麻依赖的关系:一项生态学研究。
Addiction. 2014 Jul;109(7):1101-9. doi: 10.1111/add.12508. Epub 2014 Mar 17.
8
Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series.药用大麻(Bedrolite)替代疗法治疗伴有合并症的精神病住院患者和大麻使用障碍:病例系列。
J Psychopharmacol. 2018 Mar;32(3):353-356. doi: 10.1177/0269881117735684. Epub 2017 Oct 17.
9
Medical use of cannabis. Cannabidiol: a new light for schizophrenia?医用大麻。大麻二酚:精神分裂症的新曙光?
Drug Test Anal. 2013 Jan;5(1):46-51. doi: 10.1002/dta.1425. Epub 2012 Oct 25.
10
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.急性和慢性 Delta9-四氢大麻酚与大麻二酚在 C57BL/6JArc 小鼠中的行为比较。
Int J Neuropsychopharmacol. 2010 Aug;13(7):861-76. doi: 10.1017/S1461145709990605. Epub 2009 Sep 29.

引用本文的文献

1
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.医用大麻素:基于药理学的系统评价和荟萃分析,涵盖所有相关医学适应证。
BMC Med. 2022 Aug 19;20(1):259. doi: 10.1186/s12916-022-02459-1.
2
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.大麻药物相互作用基础:促进剂、药理学和药代动力学。
Pharmacol Ther. 2019 Sep;201:25-38. doi: 10.1016/j.pharmthera.2019.05.001. Epub 2019 May 7.

本文引用的文献

1
Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series.药用大麻(Bedrolite)替代疗法治疗伴有合并症的精神病住院患者和大麻使用障碍:病例系列。
J Psychopharmacol. 2018 Mar;32(3):353-356. doi: 10.1177/0269881117735684. Epub 2017 Oct 17.
2
Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.大麻使用的持续时间、频率和类型对精神病发作后头两年复发的影响:一项观察性研究。
Lancet Psychiatry. 2016 Oct;3(10):947-953. doi: 10.1016/S2215-0366(16)30188-2. Epub 2016 Aug 23.
3
Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis.精神病患者持续使用与停止使用大麻的情况:一项系统评价和荟萃分析。
Lancet Psychiatry. 2016 Mar;3(3):215-25. doi: 10.1016/S2215-0366(15)00363-6. Epub 2016 Jan 15.
4
A systematic review of the antipsychotic properties of cannabidiol in humans.大麻二酚对人类抗精神病特性的系统评价。
Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7.
5
Reasons for cannabis use among youths at ultra high risk for psychosis.处于精神病超高风险的青少年使用大麻的原因。
Early Interv Psychiatry. 2015 Jun;9(3):207-10. doi: 10.1111/eip.12112. Epub 2013 Nov 26.
6
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.大麻二酚可抑制 THC 引起的偏执症状和海马依赖性记忆损伤。
J Psychopharmacol. 2013 Jan;27(1):19-27. doi: 10.1177/0269881112460109. Epub 2012 Oct 5.
7
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.大麻二酚抗精神病作用的批判性评价:30 年的转化研究。
Curr Pharm Des. 2012;18(32):5131-40. doi: 10.2174/138161212802884681.
8
Reasons for substance use among people with mental disorders.精神障碍患者物质使用的原因。
Addict Behav. 2012 Apr;37(4):427-34. doi: 10.1016/j.addbeh.2011.11.039. Epub 2011 Dec 4.
9
Cannabis with high cannabidiol content is associated with fewer psychotic experiences.高含量大麻素的大麻与较少的精神病体验有关。
Schizophr Res. 2011 Aug;130(1-3):216-21. doi: 10.1016/j.schres.2011.04.017. Epub 2011 May 17.
10
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.大麻二酚和Δ9-四氢大麻酚对人脑功能和精神病理学的相反影响。
Neuropsychopharmacology. 2010 Feb;35(3):764-74. doi: 10.1038/npp.2009.184. Epub 2009 Nov 18.